Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 21

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 2
Chunk 21
---
 2024 consisted of anniversary expense
receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. $63,280 of revenue recognized during both of the
six months ended March 31, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

  20  

Operating
Expenses

Operating
Expense were $172,414 for the three months ended March 31, 2025 and $ 160,135 for the same period ended 2024. The primarily operating
expense for 2025 consists of $ 136,566 of Consulting & Professional expenses and $22,500 in rent. In the same period in previous
year Consulting and Professional fees expenditure were $93,400 During the period ended 2024 research and development expenses amounted
to $40,133 constituting the second largest expense recognized during that quarter.

Operating
Expense were $292,857 For the six months ended March 31, 2025 and $ 341,982 for the same period ended 2024. The primarily operating expense
for 2025 consists of $ 221,192 of Consulting & Professional expenses and $45,000 in rent. In the same period in previous year Consulting
and Professional fees expenditure were $200,300 During the period ended 2024 research and development expenses amounted to $87,661 constituting
the second largest expense recognized during that quarter.

Other
Income

For
the three months ended March 31 2025, the Company reported a net other income of $93,995 whereas in the same period ended 2024 the Company
reported the net other expense of $(21,383). Net other income was primarily driven by the recognition of a Derivative Gain of $128,963
in 2025. For the quarter ended March 31, 2025 the Company also recognized higher interest and amortization expenses as compared to the
quarter ended 2024..

For
the six months ended March 31 2025, the Company reported a net other expense of $(360,012) whereas in the same period ended 2024 the
Company reported the net other expense of $(43,534) Net other income was primarily driven by the recognition of a Derivative Expense
in of $(287,053) in 2025. For the period ended March 31, 2025 the Company also recognized higher interest and amortization expenses as
compared to the quarter ended 202